塞来昔布(Celecoxib) - 药物靶点：COX-2_在研适应症：偏头痛，疼痛，牙痛_专利_临床

概要

基本信息

简介CELEBREX是一种非甾体抗炎药。Celecoxib具有镇痛，抗炎和退热作用。CELEBREX的作用机制被认为是通过抑制前列腺素合成，主要通过抑制COX-2而实现的。Celecoxib是体外前列腺素合成的强效抑制剂。治疗期间达到的Celecoxib浓度已经产生了体内效果。前列腺素使传入神经末梢变得敏感，并增强了缓激肽诱导动物模型疼痛的作用。前列腺素是炎症介质。由于Celecoxib是前列腺素合成的抑制剂，因此其作用机制可能是通过减少外周组织中的前列腺素而实现的。CELEBREX适用于骨关节炎（OA），类风湿性关节炎（RA），少年类风湿性关节炎（JRA），强直性脊柱炎（AS），急性疼痛，原发性痛经。它最初由辉瑞公司在1998年在美国上市，用于治疗关节炎。

药物类型

小分子化药

别名

Celecoxib (JAN/USP/INN)、p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide、AD-2111

+ [23]

靶点

COX-2

作用方式

抑制剂

作用机制

COX-2抑制剂(环氧化酶-2抑制剂)

治疗领域

肿瘤免疫系统疾病感染+ [7]

在研适应症

偏头痛疼痛牙痛+ [18]

非在研适应症

光化性角化病食管腺癌前列腺腺癌+ [49]

原研机构

Pfizer Inc.

在研机构

Upjohn EESV

Astellas Pharma, Inc.

北京德立福瑞医药科技有限公司

+ [8]

非在研机构

Pfizer Inc.

Viatris, Inc.

Pharmacia Corp.

+ [12]

权益机构

Ethypharm SAS

Dr. Reddy's Laboratories Ltd.

Scilex Pharmaceuticals, Inc.

+ [6]

最高研发阶段批准上市

首次获批日期

美国 (1998-12-31),

骨关节炎类风湿关节炎

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、优先审评 (中国)、加速批准 (美国)

登录后查看时间轴

结构/序列

分子式C17H14F3N3O2S

InChIKeyRZEKVGVHFLEQIL-UHFFFAOYSA-N

CAS号169590-42-5

关联

713

项与塞来昔布相关的临床试验

IRCT20200306046708N1

/ Suspended临床2/3期IIT

Celecoxib added to mood stabilizer for treating acute mania: A randomized, double-blind, placebo-controlled trial

开始日期2633-12-15

申办/合作机构

Mashhad University of Medical Sciences

NCT03590821

/ Not yet recruiting早期临床1期IIT

Modulating Celecoxib Induced Blood Pressure Changes by Timed Administration of Aspirin and the Human Chronobiome

To determine whether timed administration of aspirin ameliorates the effects of celecoxib on blood pressure.

开始日期2026-12-01

申办/合作机构

University of Pennsylvania

NCT06699966

/ Not yet recruiting临床4期IIT

Stony Brook Medicine Anti-Inflammatory Trial

This is an experimental study designed to measure the effect of celecoxib or minocycline on depressive symptoms in unipolar and bipolar depression. Participants will be equally randomized to either celecoxib or minocycline. All participants will complete a battery of clinical and psychological assessments prior to treatment assignment, and again after treatment completion, to assess any changes or improvements in depression.

开始日期2026-01-01

申办/合作机构

Stony Brook University

100 项与塞来昔布相关的临床结果

登录后查看更多信息

100 项与塞来昔布相关的转化医学

登录后查看更多信息

100 项与塞来昔布相关的专利（医药）

登录后查看更多信息

10,148

项与塞来昔布相关的文献（医药）

2026-01-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

A near-infrared AIE probe targeting COX-2 for imaging of Cancer cells

Article

作者: Liu, Jianxi ; Xue, Ying ; Liu, Wanhui ; Shen, Li ; Zhang, Yonglin ; Zhu, Yanping ; Chen, Shulin ; Wang, Aiping ; Xu, Lixiao ; Hu, Jiale

High expression of cyclooxygenase-2 (COX-2) in the inflammatory tumor microenvironment is a critical target for early cancer diagnosis. We designed and synthesized a series of near-infrared (NIR) fluorescent probes based on the aggregation-induced emission (AIE) mechanism for targeted COX-2 imaging. Leveraging a D-π-A quinoline-malononitrile core, we developed probes YL-180 (non-targeted control), YL-181 (celecoxib conjugate), and YL-186 (indomethacin conjugate). Notably, this work represents the first report combining this specific AIE core with established COX-2 targeting ligands, celecoxib and indomethacin, for this application. These probes exhibit characteristic AIE properties, with YL-181 showing fluorescence enhancement up to approximately 9.7-fold from pure THF in aggregated state, effectively overcoming the aggregation-caused quenching (ACQ) issue. They also possess favorable optical features including NIR emission (>650 nm) and large Stokes shifts (>200 nm). Their aggregation behavior and nanoparticle formation were characterized by DLS and TEM. In vitro cellular imaging revealed that YL-181 achieved superior tumor cell selectivity, demonstrating approximately 22-fold higher fluorescence intensity in MCF-7 cancer cells over normal HUVEC cells (around 4-fold for YL-186 over normal HUVEC cells). A competitive assay confirmed YL-181's specific COX-2 binding. Furthermore, YL-181 sensitively reflected intracellular COX-2 levels, with fluorescence decreasing by approximately 97 % from untreated upon COX-2 inhibition and increasing by around 135 % from untreated upon induction. Molecular docking and dynamics simulations provided insights into the specific binding mode and dynamic stability of YL-181 with COX-2 from an atomic perspective. In vivo imaging validated YL-181's excellent tumor targeting ability and high contrast performance in mouse models, showing a tumor-to-background ratio (TBR) of around 1.83 from normal tissue background, consistent with ex vivo organ analysis. Our highly sensitive and selective COX-2 targeted AIE probe, YL-181, holds significant potential for precise early tumor imaging.

2025-12-01·CANCER CHEMOTHERAPY AND PHARMACOLOGY

Protective effect of celecoxib against capecitabine induced hand and foot syndrome in patients with colorectal Cancer

Article

作者: Kettana, Ahmed M ; Mostafa, Tarek M ; Ghannam, Amr A ; El-Afify, Dalia R

BACKGROUND:

Hand-foot syndrome (HFS) is the most common adverse effect of capecitabine.

OBJECTIVE:

We aimed at evaluating the protective effect of celecoxib against capecitabine induced hand and foot syndrome in patients with colorectal cancer (CRC).

METHODS:

In this randomized controlled parallel study, 44 newly diagnosed patients with stage II CRC were randomly allocated into two groups; Group 1(control group; n = 22) which received 6 cycles of capecitabine-based chemotherapy (cycle is every 3 weeks) and group 2 (celecoxib group; n = 22) which received 6 cycles of capecitabine-based chemotherapy (cycle is every 3 weeks) in addition to 200 mg of oral celecoxib twice daily for 14 days of the 3-week cycle. At baseline and after the 6th chemotherapy cycle the patients' quality of life (QOL) was assessed using hand and foot syndrome (HFS) specific QOL questionnaire (HFS-14). Moreover, blood samples were collected in order to evaluate the serum levels of cyclooxygenase-2 (COX-2), tumour necrosis factor-alpha (TNF-α) and malondialdehyde (MDA). Data was analysed using paired and un-paired t-tests.

RESULTS:

At the end of the study and as compared to control group, celecoxib treated group showed significantly lower incidence of HFS (P = 0.015). Additionally, celecoxib treated group showed significant decline in the serum levels of TNF-α (P = 0.016) and MDA (P = 0.014) which was associated with non-significant difference in the serum level of COX-2 between the two groups (P = 0.476). Celecoxib was safe and well-tolerated throughout the study period.

CONCLUSION:

Celecoxib may represent a potential protective agent against capecitabine induced hand and foot syndrome in patients with colorectal cancer.

2025-11-01·NEUROPHARMACOLOGY

Persistent COX-2 upregulation in L-DOPA-induced dyskinesia is unaffected by inhibition with celecoxib

Article

作者: Del Bel, Elaine ; Dos Santos Pereira, Maurício

Neuroinflammation is a major contributor to L-DOPA-induced dyskinesia (LID), a common complication in Parkinson's disease (PD) therapy. Cyclooxygenase-2 (COX-2), a key proinflammatory enzyme, is elevated in the lesioned striatum of dyskinetic models, though its role as a causal factor or consequence remains unclear. This study addresses two aims: 1 - to explore COX-2 expression patterns in hemiparkinsonian dyskinetic mice with partial nigrostriatal lesion, correlating these patterns with the severity of abnormal involuntary movements (AIMs) and FosB/ΔFosB expression; 2- to evaluate the efficacy of COX-2 inhibitors in alleviating the established LID or preventing its development. In the first part, C57Bl/6 male mice had their AIMs intensity scored and were euthanized at 1, 7, 14, or 21 days after L-DOPA administration for molecular analysis. In the second part, mice with previously established LID were treated with either vehicle, the selective COX-2 inhibitor Celecoxib, or a non-selective COX inhibitor, Indomethacin for 5 days. An additional group received Celecoxib alongside L-DOPA for 21 days during LID development. COX-2 expression was associated with LID development after 14 days of L-DOPA treatment, correlating with AIMs severity and FosB/ΔFosB expression. COX-2 was found in striatal regions lacking tyrosine hydroxylase fibers and co-localized with neuronal markers. Although COX-2 inhibition did not reduce AIMs or COX-2 and FosB/ΔFosB expression, it significantly lowered PGE₂ levels, a downstream product of the COX-2 pathway. These results suggest that COX-2 upregulation may contribute to LID persistence through mechanisms beyond classical PGE₂-mediated neuroinflammation.

509

项与塞来昔布相关的新闻（医药）

2025-08-13

·今日头条

再取进展！上海交大团队发现黄连素可抑制肿瘤术后复发，数据亮眼

【导读】黄连素已被报道是一种安全有效的药物，可减少结肠息肉切除术后结直肠腺瘤的复发。 8月11日，上海交通大学研究团队在期刊《Cell Reports Medicine》上发表了研究论文，题为“Berberine for preventing colorectal adenoma recurrence and neoplasm occurrence: 6-Year follow-up of a randomized clinical trial”，本研究中，研究人员进行了一项在治疗后观察期的延伸随访。研究人员旨在评估黄连素对腺瘤复发的长期保护作用。在之前完成两年随机试验的 895 名患者中，研究人员在全国 6 个省份的 7 个临床中心招募了 781 名患者。主要结局指标是腺瘤复发。从 2018 年 12 月 29 日至 2024 年 10 月 10 日，648 名患者在随访期间至少接受了一次结肠镜检查。黄连素的保护作用在治疗停止后至少持续 6 年，腺瘤复发率更低（34.7% 对 52.1%），肿瘤发生率也更低（63.4% 对 71.0%）。黄连素可能成为息肉切除术后预防腺瘤复发的一种潜在长期预防药物。 https://www-cell-com.libproxy1.nus.edu.sg/cell-reports-medicine/fulltext/S2666-3791(25)00366-0 背景知识 01 作为结直肠癌的前驱病变，结直肠腺瘤在内镜切除术后具有较高的复发率。复发性结直肠腺瘤由于至少 10 年的基因改变，会增加结直肠癌的发病率。化学预防干预措施已被证明能降低结直肠腺瘤的复发率，且已发现几种相关的药物和营养补充剂：叶酸、阿司匹林、塞来昔布、钙和维生素 D。然而，其中一些药物和补充剂缺乏长期随访数据，或者由于潜在的副作用其使用受到限制。传统医学在癌症化学预防中发挥着越来越重要的作用。黄连素是从中国草药黄连中分离出来的，几个世纪以来一直用于治疗腹泻和肠炎。最近的动物研究报道，黄连素可以通过改变微生物群组成抑制结直肠肿瘤发生途径并影响肿瘤微环境，使其成为结直肠癌化学预防的潜在药物。研究进展 02 在这项 CBAR 试验的治疗后随访研究中，研究人员发现，在息肉切除患者中，为期 2 年的黄连素治疗在中位观察时间 78.0 个月（6 年）内对结直肠腺瘤复发和肿瘤发生具有延长的化学预防效果。与 CBAR 试验期间相比，黄连素在治疗后的化学预防效果更为显著，结直肠腺瘤的复发率进一步降低。许多体内和体外研究均表明，黄连素能够抑制与结直肠肿瘤发生途径相关的有害微生物群，并调节肿瘤微环境。除了通过肠道微生物群抑制结直肠癌外，黄连素还被广泛证明可通过肠道微生物群相互作用来解决高脂血症、糖尿病和其他代谢紊乱。鉴于黄连素的持久作用，间歇给药可能在最大程度上发挥黄连素对结直肠腺瘤复发的化学预防作用，同时将副作用降至最低。间歇期及其相关机制有待进一步分析。在本研究中，结肠镜检查的中位随访间隔为 3 年，比一些西方国家的研究更频繁。各国的监测间隔时间往往因腺瘤发病率和当地情况而异。例如，在美国，目前的指南建议低风险患者每 5 - 10 年随访一次，有进展期腺瘤或传统锯齿状腺瘤的患者每 3 - 5 年随访一次，有超过 10 个腺瘤的患者每年随访一次。相比之下，中国共识指南建议所有患者在息肉切除术后每 1 - 3 年随访一次，对于有进展期结直肠腺瘤的患者，随访间隔应缩短至 3 - 6 个月。中国共识指南基于中国患者的特点和医疗条件，总结了近期临床试验、荟萃分析、系统评价和专家意见的结果。结直肠腺瘤和肿瘤的无病期研究结论 03 综上，在治疗后 6 至 8 年，黄连素能够预防结直肠腺瘤复发和结直肠肿瘤发生，且无需持续补充。因此，它可能是结直肠腺瘤的重要二级化学预防剂，也是结直肠癌的潜在候选药物。参考资料： https://www-cell-com.libproxy1.nus.edu.sg/cell-reports-medicine/fulltext/S2666-3791(25)00366-0 【关于投稿】转化医学网（360zhyx.com）是转化医学核心门户，旨在推动基础研究、临床诊疗和产业的发展，核心内容涵盖组学、检验、免疫、肿瘤、心血管、糖尿病等。如您有最新的研究内容发表，欢迎联系我们进行免费报道（公众号菜单栏-在线客服联系），我们的理念：内容创造价值，转化铸就未来！转化医学网（360zhyx.com）发布的文章旨在介绍前沿医学研究进展，不能作为治疗方案使用；如需获得健康指导，请至正规医院就诊。责任声明：本稿件如有错误之处，敬请联系转化医学网客服进行修改事宜！微信号：zhuanhuayixue 热门推荐活动点击免费报名线上｜2025年8月20日 ▶ 极限突破，先机必争：单细胞全转录组空间多组学技术 CosMx SMI 的前沿解析北京｜2025年9月18日 ▶ 转化医学私享会：医工交叉融合创新推动医疗高质量发展北京｜2025年9月19-20日 ▶ 第六届单细胞技术应用研讨会暨空间组学前沿研讨会上海｜2025年11月20-23日 ▶ 第八届上海国际肿瘤内科学论坛（8th SIMOS）上海｜2025年12月10日 ▶ 第五届现代临床分子诊断研讨会点击对应文字查看详情

临床研究临床结果

2025-08-12

·生物世界

Cell子刊：房静远/陈萦晅团队临床研究证实，黄连素可长期预防结直肠腺瘤复发及肿瘤发生

撰文丨王聪编辑丨王多鱼排版丨水成文作为结直肠癌的癌前病变，结直肠腺瘤在内镜切除术后具有较高的复发率。复发性结直肠腺瘤由于至少 10 年的基因异常改变的积累，可增加结直肠癌的发病率。化学预防干预措施已被证实能有效降低结直肠腺瘤的复发率，而且已发现几种相关的药物和营养补充剂：叶酸、阿司匹林、塞来昔布、钙和维生素 D。然而，其中一些药物和补充剂缺乏长期的跟踪数据，或者由于潜在的副作用其使用受到了限制。传统医学在癌症化学预防方面发挥着越来越重要的作用。小檗碱（分子式为C20H18NO4），是从中药材黄连中提取出来的，因此也叫黄连素，几个世纪以来在中国一直被用于治疗腹泻和肠炎。近期的动物研究报道，小檗碱能够抑制结直肠肿瘤发生途径，并通过改变肠道微生物群组成影响肿瘤微环境，使其成为结直肠癌的一种潜在化学预防剂。 2025 年 8 月 11 日，上海交通大学医学院附属仁济医院房静远、陈萦晅等人在 Cell 子刊 Cell Reports Medicine 上发表了题为：Berberine for preventing colorectal adenoma recurrence and neoplasm occurrence: 6-Year follow-up of a randomized clinical trial 的研究论文【1】。这项回顾性队列研究是对该团队之前的一项临床试验（NCT02226185）在治疗后观察期的延伸随访，旨在评估小檗碱对结直肠腺瘤复发的长期保护作用，结果显示，小檗碱在治疗停止后至少 6 年仍有保护作用，小檗碱治疗组的腺瘤复发率较低（34.7% vs 52.1%），肿瘤发生率也较低（63.4% vs 71.0%），因此，小檗碱可能作为息肉切除术后预防结直肠腺瘤复发的潜在长期预防药物。 2020 年，房静远、陈萦晅团队在《柳叶刀》子刊 The Lancet Gastroenterology & Hepatology 上发表论文【2】，这项双盲、随机、安慰剂对照的多中心临床试验，评估了小檗碱（每天两次，每次0.3克）对结直肠腺瘤复发的化学预防效果，结果显示，在为期两年的试验中，小檗碱治疗组的结直肠腺瘤和任何类型的息肉样病变的复发率显著低于安慰剂组（36% vs 47%），且未出现严重不良事件。这项临床研究表明，小檗碱（每天两次，每次0.3克）可安全有效地降低结直肠腺瘤的复发风险，并可作为息肉切除术后化学预防的一种选择。在这项最新研究中，为方便起见，研究团队将这项随机临床试验命名为小檗碱预防腺瘤复发试验（CBAR）。在为期两年的随机 CBAR 试验结束后，研究团队开展了这项回顾性研究，命名为为 CBAR 随访扩展（CBAR-FE）研究，研究团队将 CBAR 试验延长，对试验参与者进行了中位数为 6 年的持续随访。目的是评估小檗碱在停止补充后对结直肠腺瘤切除术后复发的长期预防保护作用。研究团队在之前完成的为期两年的随机临床试验的 895 名患者中招募了 781 名患者（来自全国 6 个省份的 7 个临床中心），主要结局指标为腺瘤复发。在 2018 年 12 月 29 日至 2024 年 10 月 10 日期间，648 名患者在随访期间至少接受过一次结肠镜检查。结果显示，相比对照组，小檗碱的保护作用在治疗停止后至少持续 6 年，腺瘤复发率更低（34.7% vs 52.1%），肿瘤发生率也更低（63.4% vs 71.0%）。小檗碱可能成为息肉切除术后预防腺瘤复发的一种潜在长期预防药物。该研究的核心发现：小檗碱可预防腺瘤在治疗后的 6 年随访期内复发；小檗碱还能降低结直肠肿瘤和非进展期腺瘤的发生率；小檗碱有望成为息肉切除术后化学预防的候选药物。论文链接： 1. https://www-cell-com.libproxy1.nus.edu.sg/cell-reports-medicine/fulltext/S2666-3791(25)00366-0 2. https://www-thelancet-com.libproxy1.nus.edu.sg/journals/langas/article/PIIS2468-1253(19)30409-1/abstract 设置星标，不错过精彩推文开放转载欢迎转发到朋友圈和微信群微信加群为促进前沿研究的传播和交流，我们组建了多个专业交流群，长按下方二维码，即可添加小编微信进群，由于申请人数较多，添加微信时请备注：学校/专业/姓名，如果是PI/教授，还请注明。点在看，传递你的品味

2025-08-06

·GlobeNewswire-Health Care

Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development‐stage biotechnology company developing new medicines to treat pain and fatigue-related disorders, announced today that it will report second quarter 2025 financial results on Wednesday, August 13, 2025 before the open of the financial markets. About Dogwood Therapeutics Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Dogwood research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary, non-opioid, NaV 1.7 analgesic program is centered on our lead development candidate, Halneuron®, which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic chemotherapy-induced neuropathic pain (“CINP”). Interim data from the ongoing Halneuron® Phase 2 CINP study are expected in Q4 of 2025. Dogwood’s antiviral program includes IMC-1 and IMC-2, which are novel, proprietary, fixed-dose combinations of anti-herpes antivirals and the anti-inflammatory agent celecoxib. These combination antiviral approaches are being applied to the treatment of illnesses believed to be related to reactivation of previously dormant herpesviruses, including fibromyalgia (“FM”) and Long-COVID (“LC”). IMC-1 is poised to progress into Phase 3 development as a treatment for FM and is the focus of external partnership activities. IMC-2 has been assessed in both active control and double-blind, placebo-controlled clinical trials and, in both cases, demonstrated successful reduction of the fatigue associated with LC. The company has reached an agreement with FDA on using reduction in fatigue as the primary endpoint for future IMC-2 LC research. For more information, please visit www.dwtx.com. Forward-Looking Statements Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood’s product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2024, which has been filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law. Contact: IR@dwtx.com

临床2期财报

100 项与塞来昔布相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00567	塞来昔布	L01XX33 M01AH01	DB00482

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
偏头痛	美国	Scilex Pharmaceuticals, Inc.	2020-05-05
疼痛	日本	Astellas Pharma, Inc.	2011-12-22
牙痛	日本	Viatris Pharmaceutical GK	2011-12-22
滑囊炎	日本	Viatris Pharmaceutical GK	2009-06-17
颈臂综合征	日本	Astellas Pharma, Inc.	2009-06-17
颈臂综合征	日本	Viatris Pharmaceutical GK	2009-06-17
腰痛	日本	Viatris Pharmaceutical GK	2009-06-17
腰痛	日本	Astellas Pharma, Inc.	2009-06-17
肩周炎	日本	Astellas Pharma, Inc.	2009-06-17
肌腱病	日本	Viatris Pharmaceutical GK	2009-06-17
肌腱病	日本	Astellas Pharma, Inc.	2009-06-17
腱鞘炎	日本	Viatris Pharmaceutical GK	2009-06-17
镇痛	日本	Viatris Pharmaceutical GK	2007-01-26
炎症	日本	Viatris Pharmaceutical GK	2007-01-26
幼年特发性关节炎	美国	Upjohn US 2 LLC	2006-12-15
原发性痛经	美国	Upjohn US 2 LLC	2001-10-18
急性疼痛	中国	Viatris Pharmaceuticals LLC	2000-08-01
强直性脊柱炎	奥地利	Upjohn EESV	2000-03-29
强直性脊柱炎	比利时	Upjohn EESV	2000-03-29
强直性脊柱炎	塞浦路斯	Upjohn EESV	2000-03-29

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
先兆偏头痛	申请上市	加拿大	Scilex Holding Co.	2023-12-26
无先兆偏头痛	申请上市	加拿大	Scilex Holding Co.	2023-12-26
光化性角化病	临床3期	美国	Dr. Reddy's Laboratories Ltd. (Russia)	2017-02-14
痛风性关节炎	临床3期	美国	Viatris, Inc.	2008-02-01
痛风性关节炎	临床3期	加拿大	Viatris, Inc.	2008-02-01
痛风性关节炎	临床3期	哥伦比亚	Viatris, Inc.	2008-02-01
痛风性关节炎	临床3期	哥斯达黎加	Viatris, Inc.	2008-02-01
痛风性关节炎	临床3期	墨西哥	Viatris, Inc.	2008-02-01
痛风性关节炎	临床3期	秘鲁	Viatris, Inc.	2008-02-01
痛风性关节炎	临床3期	菲律宾	Viatris, Inc.	2008-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00652925 (FDA_CDER) 人工标引	临床3期	幼年特发性关节炎	-	CELECOXIB 3 mg/kg	鑰繭衊觸襯艱窪鹽鹹糧(遞憲膚醖築衊願網壓壓) = 襯鑰繭獵繭鬱獵襯膚襯鏇繭艱觸齋糧壓淵蓋膚 (憲構範製遞鬱鑰顧鏇網 )	积极	2025-07-29
				CELECOXIB 6 mg/kg	鑰繭衊觸襯艱窪鹽鹹糧(遞憲膚醖築衊願網壓壓) = 壓糧願壓淵網憲糧壓窪鏇繭艱觸齋糧壓淵蓋膚 (憲構範製遞鬱鑰顧鏇網 )
ASCO2025	N/A	晚期头颈部鳞状细胞癌	97	Dual Oral Metronomic Therapy (OMT)	醖糧顧齋齋糧艱積願襯(簾鹹憲夢遞鏇醖壓獵築) = 齋選襯鹽淵憲窪製積齋網艱簾遞繭鑰衊願憲選 (艱鑰範鹹選醖鹹廠艱膚 ) 更多	积极	2025-05-30
				Triple Oral Metronomic Therapy (OMT)	醖糧顧齋齋糧艱積願襯(簾鹹憲夢遞鏇醖壓獵築) = 淵鏇窪醖製願鹹獵選醖網艱簾遞繭鑰衊願憲選 (艱鑰範鹹選醖鹹廠艱膚 ) 更多
NCT05974501 (CTgov)	临床4期	关节置换术并发症 \| 膝关节炎 \| 术后疼痛	84	Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Preoperative Adductor Canal Block Group)	繭繭選遞鬱廠構鬱顧艱(簾淵範積繭構製鏇製壓) = 艱製襯夢餘廠蓋齋醖憲鏇遞願獵製襯觸遞繭廠 (鑰齋廠膚遞壓衊網憲簾, 鏇糧遞積鑰憲遞築醖憲 ~ 願鏇鑰鑰衊淵鬱夢鹽築) 更多	-	2025-02-12
				Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Postoperative Adductor Canal Block Group)	繭繭選遞鬱廠構鬱顧艱(簾淵範積繭構製鏇製壓) = 艱獵遞夢艱廠觸鹹網鹽鏇遞願獵製襯觸遞繭廠 (鑰齋廠膚遞壓衊網憲簾, 鬱選鏇鹹顧壓鬱衊顧顧 ~ 壓襯製簾齋顧窪餘醖醖) 更多
NCT04162873 (CTgov)	临床2期	下咽癌 \| 口腔鳞状细胞癌复发 \| 鼻窦癌 ... 更多	13	Quality-of-Life Assessment+celecoxib (Celecoxib Arm)	鬱選製獵簾窪選築願鏇(餘製網衊選鹹夢範積醖) = 憲顧憲餘構憲壓窪襯鑰蓋構遞襯醖淵觸鹽繭襯 (鏇製廠獵窪齋顧夢艱鏇, 9.19) 更多	-	2025-02-12
				Placebo (Placebo Arm)	鬱選製獵簾窪選築願鏇(餘製網衊選鹹夢範積醖) = 選鏇築餘襯構鏇觸願鏇蓋構遞襯醖淵觸鹽繭襯 (鏇製廠獵窪齋顧夢艱鏇, 20.04) 更多
NCT01150045 (CALGB/SWOG 80702, ASCO_GI2025)	临床3期	III期结肠癌辅助 ctDNA positive	-	Celecoxib + FOLFOX	窪鹽範鹽壓鹽獵襯淵鑰(構選製淵齋淵壓遞襯壓) = 願積積鬱鏇糧鑰遞壓鏇齋壓醖鏇範遞鹽鹹顧鹹 (廠齋簾繭夢鹹襯範積簾 )	积极	2025-01-23
				Placebo + FOLFOX	窪鹽範鹽壓鹽獵襯淵鑰(構選製淵齋淵壓遞襯壓) = 鹹顧鑰艱築鑰膚製衊醖齋壓醖鏇範遞鹽鹹顧鹹 (廠齋簾繭夢鹹襯範積簾 )
NCT03643744 (CTgov)	临床1期	光化性角化病	12	Celecoxib 200mg (PDT + Celecoxib)	醖願壓糧齋襯淵範鬱齋(齋餘製蓋鹹糧膚鹽繭構) = 顧夢鹹廠鹽餘範選淵壓襯鑰蓋鹹壓壓襯窪願範 (願淵廠鑰製遞網醖願餘, 107) 更多	-	2024-12-19
				Placebo (PDT + Placebo)	醖願壓糧齋襯淵範鬱齋(齋餘製蓋鹹糧膚鹽繭構) = 鏇顧鑰窪膚繭築夢築鬱襯鑰蓋鹹壓壓襯窪願範 (願淵廠鑰製遞網醖願餘, 19) 更多
NCT04765644 (ASCENT, CTgov)	临床4期	-	44	celecoxib+L-arginine (Celecoxib)	醖積襯鏇願齋糧簾遞淵(蓋艱淵範壓鑰淵蓋網壓) = 網鬱構積壓淵範鬱蓋鹽積網糧簾襯鹽艱鏇襯窪 (艱膚範壓觸膚顧膚壓鹹, 0.35) 更多	-	2024-10-28
				Placebo+L-arginine + placebo (Placebo)	醖積襯鏇願齋糧簾遞淵(蓋艱淵範壓鑰淵蓋網壓) = 選醖觸窪積壓齋簾糧願積網糧簾襯鹽艱鏇襯窪 (艱膚範壓觸膚顧膚壓鹹, 0.33) 更多
NCT03859024 (CTgov)	临床4期	尿道狭窄 \| 术后疼痛	48	Acetaminophen+Oxycodone+Ibuprofen 800 mg (Standard Protocol)	膚糧糧夢壓膚範築膚蓋(廠夢襯襯願鑰壓鹽壓範) = 鏇遞餘網製廠構膚蓋築夢齋獵鏇淵積簾顧顧鏇 (襯窪遞醖簾窪願憲鹹繭, 齋範淵獵餘壓夢餘壓壓 ~ 襯簾繭襯範獵襯艱壓鑰) 更多	-	2024-09-19
				Acetaminophen+Oxycodone+Dexamethasone+Ibuprofen 800 mg+Bupivacaine+celebrex+Gabapentin (Enhanced Recovery Protocol)	膚糧糧夢壓膚範築膚蓋(廠夢襯襯願鑰壓鹽壓範) = 構齋窪夢壓遞顧觸選衊夢齋獵鏇淵積簾顧顧鏇 (襯窪遞醖簾窪願憲鹹繭, 餘蓋積顧蓋繭糧壓鹽顧 ~ 齋餘壓顧廠膚遞壓網願) 更多
NCT05077969 (CTgov)	临床2期	SARS-CoV-2 急性呼吸道疾病	4	Famotidine+celecoxib (Group 1 (Study Product))	網夢積蓋顧糧鏇選網願 = 壓衊膚簾觸鑰觸顧鏇鏇齋鹹窪製鹹築鹹顧積醖 (築襯鏇繭築觸製餘鹹簾, 衊鹽範範顧簾糧鏇遞膚 ~ 糧鬱襯憲醖淵製鏇網積) 更多	-	2024-07-09
				Placebo (Group 2 (Reference Therapy))	網夢積蓋顧糧鏇選網願 = 膚選襯衊醖醖範構顧餘齋鹹窪製鹹築鹹顧積醖 (築襯鏇繭築觸製餘鹹簾, 觸糧選網鬱願淵簾壓糧 ~ 顧顧齋積構簾觸構顧鑰) 更多
NCT04015908 (CTgov)	临床4期	-	100	Pregabalin+Acetaminophen+Oxycodone+celecoxib (Multi-modal)	艱積積憲淵糧蓋壓範齋(積壓壓構膚襯憲糧網鑰) = 鏇憲觸鬱衊鑰遞選簾範膚網簾廠鏇醖鏇廠壓獵 (構淵鬱遞憲醖憲憲鏇願, 遞願築膚簾鹽顧積顧網 ~ 膚鹽鏇糧衊齋鹹蓋鹹鹹) 更多	-	2024-07-08
				Percocet (Control)	艱積積憲淵糧蓋壓範齋(積壓壓構膚襯憲糧網鑰) = 鹹醖鏇製糧餘選蓋觸鹹膚網簾廠鏇醖鏇廠壓獵 (構淵鬱遞憲醖憲憲鏇願, 蓋蓋壓築鏇簾簾積膚蓋 ~ 衊廠願範憲願餘遞遞願) 更多